GI Dynamics has taken all necessary COVID-19 precautions to ensure patient safety, which remains top priority. Patient screening for the STEP-1 pivotal trial of EndoBarrier has reopened at select sites and enrollment will be conducted according to site requirements and CDC/FDA guidelines.
GI Dynamics, Inc (GID) is the developer of EndoBarrie which is the first endoscopicallydelivered device therapy for the treatment of type 2 diabetes and obesity. GI.
View today’s GID share price, options, bonds, hybrids and warrants. View announcements, advanced pricing charts, trading status, fundamentals, dividend information, peer.
GI Dynamics , Inc. (GID.AX) ( ASX :GID) posted its earnings results on Thursday, May, 16th. The company reported ($0.12) earnings per share for the quarter. View GI Dynamics.
7/15/2020 · GI Dynamics ®, Inc. (ASX:GID) is the developer of EndoBarrier ®, the first endoscopically delivered medical device for the treatment of type 2 diabetes and the reduction of obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only.
BOSTON and SYDNEY – 22 June 2020- GI Dynamics ® Inc. ( ASX :GID) (‘GID’ or the ‘Company’), a medical device company that is developing EndoBarrier ® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020 and, in accordance with ASX Listing Rule 3.13.2, is pleased to confirm that each of the resolutions put to stockholders as set …
3/30/2020 · GI Dynamics ®, Inc. (ASX:GID) is the developer of EndoBarrier ®, the first endoscopically-delivered medical device for the treatment of type 2 diabetes and the reduction of obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only.
3/2/2020 · About GI Dynamics. GI Dynamics®, Inc. (ASX:GID) is the developer of EndoBarrier®, the first endoscopically delivered medical device for the treatment of type 2 diabetes and the reduction of obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only. EndoBarrier is subject to an Investigational Device Exemption by the FDA in the United States and is entering.
GI Dynamics delisted from the Official List of the Australian Stock Exchange (ASX) on July 22, 2020. To access past ASX announcements please visit: Click Here, 11/5/2020 · BOSTON and SYDNEY — 22 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020 and, in accordance with ASX…
